论文部分内容阅读
肺癌是常见的恶性肿瘤之一,一经发现大多已失去手术机会。支气管动脉化疗灌注术(BAI),作为中晚期肺癌的非手术疗法应视为首选,其近期疗效(指症状、瘤体大小变化的评估),已为国内同行大量报道,但其远期疗效(指生存期随访),报道不多。本文66例不能手术切除的肺癌,经支气管动脉介入治疗,且对生存期随访(电话或信访),旨在探讨如何进一步规范介入治疗方法,减少并发症,提高疗效。
Lung cancer is one of the most common malignancies and most of them have lost surgical opportunities. Bronchial arterial chemoembolization (BAI) is considered as the first choice for non-surgical treatment of advanced lung cancer. Its short-term efficacy (evaluation of symptoms and changes in tumor size) has been widely reported by domestic counterparts, but its long-term efficacy ( Refers to the survival period follow-up), there are not many reports. This article 66 cases of lung cancer can not be treated by bronchial artery interventional therapy, and follow-up on the survival period (telephone or letters), aims to explore how to further standardize interventional treatment, reduce complications and improve efficacy.